HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mackenzie, J. W. Articles by Clark, I. Search for Related Content PubMed PubMed Citation Articles by Mackenzie, J. W. Articles by Clark, I.

The Annals of Thoracic Surgery, Vol 38, 133-139, Copyright © 1984 by The Society of Thoracic Surgeons

ARTICLES

Urinary catabolites of ribonucleic acid as cancer markers: a preliminary report of their use in patients with lung cancer

JW Mackenzie, RJ Lewis, GE Sisler, W Lin, J Rogers and I Clark

Rats with aflatoxin-B1-induced hepatomas and dimethylnitrosamine- induced nephroblastomas excreted greater than normal amounts of urinary modified nucleosides and bases, catabolites of ribonucleic acid (RNA). Although both neoplasms caused increased excretions of the same catabolites, their quantitative profiles differed, suggesting that it may be possible to distinguish between tumors. Rats with transplanted tumors (e.g., hepatomas and osteogenic sarcomas) did not excrete elevated levels of urinary RNA catabolites until approximately 20 days after transplantation despite rapid growth of the tumor for the first 15 days. These data suggest that the source of the elevated levels of these excretory products may be the host's tissue RNA. Preliminary studies in human beings with lung cancer showed marked elevation of one or more urinary RNA catabolites. Resection of the diseased tissue in 2 patients caused a drop in levels. The measurement of urinary RNA catabolites may be useful in the diagnosis, prognosis, and evaluation of therapy in patients with lung cancer.